Publications

Abstract Introduction/Purpose –Cerebral arterial blood flow contributes directly to stroke, plays a role in aneurysm progression, and has increasingly been linked to neurological disease. The purpose of this research was to establish baselines for cerebral flow in various arteries of healthy individuals, which can be used as controls when studying cerebrovascular disease. Materials/Methods – Non‐contrast … Continued

Pharmacogenomic testing has emerged as an aid in clinical decision making for psychiatric providers, but more data is needed regarding its utility in clinical practice and potential impact on patient care. In this cross-sectional study, we determined the real-world prevalence of pharmacogenomic actionability in patients receiving psychiatric care. Potential actionability was based on the prevalence … Continued

Purpose: Patients diagnosed with major depressive disorder do not consistently achieve adequate symptom reduction. CPIC and FDA have published prescribing recommendations for psychiatric-related medications impacted by pharmacogenomics (PGx) and phenoconversion. There are limited analyses on allele-specific copy number variations (CNVs) and emerging biomarkers such as the CYP2C-TG haplotype. In this study, we evaluated the prevalence … Continued

Purpose: Historically, tracking behavioral health symptoms has been challenging. Mobile health apps for patient-reported outcomes (PRO) can administer measurement-based care to track patients’ symptom severity and be combined with Apple Health kit wearables. These tools can provide unique insights for real-time tracking of patient sleep quality. Methods: This is a retrospective study of de-identified records … Continued

Background/Objective: The purpose of this study was to compare patient-reported and passive-sensor-based measures of sleep in patients with a psychiatric diagnosis. Design: This was a retrospective study of patients being treated for psychiatric disease who received the Tempus nP pharmacogenomics assay and used the TempusPRO application (app). We extracted patient-reported sleep scores from standard psychiatric … Continued

Introduction: Less than 40% of patients with major depressive disorder (MDD) achieve clinical remission after first-line antidepressant treatment. Pharmacogenomic (PGx) testing may improve drug selection and/or dosing in patients with genetic variation(s) that alter drug pharmacokinetics through CYP2D6 and CYP2C19. The Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines and Food and Drug Administration (FDA) Table of … Continued

Background – Patients with neuropsychiatric illness have inconsistent responses to medications. Pharmacogenomic testing (PGx) helps identify patients who may better respond to certain medications or carry a greater risk of adverse events. Mobile health apps, like TempusPRO, administer measurement-based care (MBC) to track symptom severity longitudinally and in real-time. Here, we combine PGx and MBC … Continued

Pharmacogenomic (PGx) testing has emerged as a compelling strategy that clinicians can use to inform antidepressant medication selection and dosing, but the clinical efficacy of this strategy has been questioned. We systematically reviewed and meta-analyzed clinical trials for an association between the use of PGx-guided antidepressant therapy and depressive symptom remission in patients with major … Continued

Objectives Partial response to pharmacotherapy is common in major depressive disorder (MDD) and many patients require alternative pharmacotherapy or augmentation, including adjunctive L-methylfolate. Given that L-methylfolate augmentation is rarely included in major clinical practice guidelines, we sought to systematically review evidence for L-methylfolate augmentation in adults with MDD and to examine its efficacy meta-analytically. Methods We … Continued